

LIST OF TABLES


	Page
Table I	10
Table 1.1	19
Table 1.2	19
Table 1.3	20
Table 1.4	20
Table 1.5	21
Table 1.6	21
Table 1.7	22
Table 1.8	22
Table 1.9	22
Table 1.10	23
Table 1.11	24
Table 1.12	25
Table 1.13	26
Table 1.14	27
Table 2.1	33
Table 2.2	34
Table 2.3	34
Table 2.4	35
Table 2.5	35
Table 2.6	36
Table 2.7	36
Table 2.8	37
Table 2.9	38
Table 2.10	38
Table 2.11	39
Table 2.12	40
Table 2.13	43



	Page	
Table 2.14	Grading, multifocality and multicentricity of invasive breast cancer (N=3,318)	43
Table 2.15	Biological characteristics of invasive breast cancer (N=3,318)	44
Table 2.16	Biological subtypes of invasive tumours by cancer stage (N=2,945)	45
Table 2.17	Histological type, grading, multifocality and multicentricity of in situ breast cancer (N=520)	46
Table 2.18	Biological characteristics of in situ breast cancer (N=520)	46
Table 2.19	Use of surgery for patients with invasive or in situ cancer	48
Table 2.20	Coverage of regional lymph nodes by adjuvant locoregional radiotherapy (N=1,184)	52
Table 2.21	Use of chemotherapy by age group and cancer stage at diagnosis (N=3,187)	53
Table 2.22	Number of treatment modalities by cancer stage (N=3,747)	61
Table 2.23	Follow-up of 17,877 patients	62
Table 2.24	Locoregional recurrence by type of surgery received and cancer stage at diagnosis	63
Table 2.25	Sites involved in locoregional recurrence (N=579)	63
Table 2.26	Organs involved in distant recurrence (N=706)	64
Table 2.27	Time for organ specific metastasis and distribution of the biological subtypes of patients	64
Table 2.28	Locoregional and distant recurrence among invasive breast cancer patients by cancer stage (N=14,751)	65
Table 2.29	Characteristics of breast cancer-specific deaths (N=226)	66
Table 3.1	Five most common forms of discomfort after surgery (N=3,348)	70
Table 3.2	Five most common forms of discomfort after radiotherapy (N=1,839)	70
Table 3.3	Five most common forms of discomfort after chemotherapy (N=1,630)	71
Table 3.4	Five most common forms of discomfort after endocrine therapy (N=2,043)	71
Table 3.5	Five most common forms of discomfort after anti-HER2 targeted therapy (N=478)	72
Table 3.6	Psychosocial impact of breast cancer	73
Table 3.7	Psychosocial adjustments and coping strategies for survivorship	74

LIST OF FIGURES

	Page
Figure I	6
Figure II	10
Figure 1.1	15
Figure 1.2	16
Figure 1.3	16
Figure 1.4	16
Figure 1.5	17
Figure 1.6	17
Figure 1.7	17
Figure 1.8	18
Figure 1.9	18
Figure 1.10	19
Figure 1.11	23
Figure 2.1	33
Figure 2.2	34
Figure 2.3	37
Figure 2.4	38
Figure 2.5	41
Figure 2.6	41
Figure 2.7	42
Figure 2.8	42
Figure 2.9	49
Figure 2.10	49
Figure 2.11	49
Figure 2.12	49
Figure 2.13	50
Figure 2.14	50
Figure 2.15	50
Figure 2.16	51
Figure 2.17	52



	Page
Figure 2.18 Use of locoregional radiotherapy among patients who underwent mastectomy by cancer stage (N=2,047)	52
Figure 2.19 Chemotherapy treatment by cancer stage (N=3,217)	53
Figure 2.20 Generation of chemotherapy drugs used by biological subtype in neoadjuvant setting (N=358)	54
Figure 2.21 Type of first generation chemotherapy drugs (non-HER2 regimen) used in adjuvant setting (N=112)	55
Figure 2.22 Type of second generation chemotherapy drugs (non-HER2 regimen) used in adjuvant setting (N=378)	55
Figure 2.23 Type of third generation chemotherapy drugs (non-HER2 regimen) used in adjuvant setting (N=438)	55
Figure 2.24 Type of HER2 regimens used in adjuvant setting (N=211)	55
Figure 2.25 Generation of chemotherapy drugs used by biological subtype in adjuvant setting (N=1,182)	56
Figure 2.26 Generation of chemotherapy drugs used by cancer stage in adjuvant setting (N=1,256)	57
Figure 2.27 Generation of chemotherapy drugs used by biological subtype in palliative setting (N=63)	58
Figure 2.28 Use of endocrine therapy by cancer stage (N=3,747)	59
Figure 2.29 Forms of endocrine therapy by age group (N=2,360)	59
Figure 2.30 Use of anti-HER2 targeted therapy in HER2 positive patients by cancer stage (N=511)	60
Figure 2.31 Type of complementary and alternative therapies used (N=950)	61
Figure 3.1 Level of physical discomfort after surgery (N=17,228)	69
Figure 3.2 Level of physical discomfort by type of surgery (N=3,330)	70
Figure 3.3 Level of physical discomfort after radiotherapy (N=1,839)	70
Figure 3.4 Level of physical discomfort after radiotherapy by irradiated regions (N=1,009)	70
Figure 3.5 Level of physical discomfort after chemotherapy (N=1,630)	71
Figure 3.6 Level of physical discomfort after endocrine therapy (N=2,043)	71
Figure 3.7 Level of physical discomfort after anti-HER2 targeted therapy (N=478)	72
Figure 3.8 Level of physical discomfort after complementary and alternative therapies (N=931)	72
Figure 3.9 Change in outlook on life by age group (N=3,257)	73
Figure 3.10 Change in self-image by age group (N=3,249)	74
Figure 3.11 Level of worry about recurrence by age group (N=3,222)	74